U.S. markets closed

Minerva Neurosciences, Inc. (NERV)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
1.3500-0.0600 (-4.26%)
At close: 4:00PM EDT
1.4300 +0.08 (+5.93%)
After hours: 07:59PM EDT
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close1.4100
Bid1.3500 x 2200
Ask1.3900 x 2200
Day's Range1.3500 - 1.4500
52 Week Range1.3500 - 4.1150
Avg. Volume654,187
Market Cap57.674M
Beta (5Y Monthly)1.07
PE Ratio (TTM)N/A
EPS (TTM)-0.8190
Earnings DateNov 01, 2021 - Nov 05, 2021
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
-25% Est. Return

Subscribe to Yahoo Finance Plus to view Fair Value for NERV

Learn more
View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Minerva Neurosciences, Inc
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion. Pfizer also spends a leading amount on research and development, close to $8 billion annually. While Pfizer historically sold many types of healthcare products and chemicals, now, prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, cardiovascular treatment Eliquis, and immunology drug Xeljanz. Pfizer sells these products globally, with international sales representing close to 50% of its total sales. Within international sales, emerging markets are a major contributor.
    Fair Value
    Economic Moat
    6 days agoMorningstar
View more
  • GlobeNewswire

    Minerva Neurosciences Announces Promotion of Geoff Race to President

    Frederick Ahlholm is Named Chief Financial Officer as Company Prepares to Submit a Pre-NDA Meeting Request to FDA WALTHAM, Mass., Oct. 11, 2021 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that Geoff Race, current Executive Vice President, Chief Financial Officer and Chief Business Officer of Minerva, has been promoted to President

  • Benzinga

    15 Stocks Moving in Friday's Pre-Market Session

    Gainers Progenity, Inc. (NASDAQ: PROG) rose 33% to $2.02 in pre-market trading after jumping over 40% on Thursday. Iterum Therapeutics plc (NASDAQ: ITRM) rose 25.1% to $0.6984 in pre-market trading after dropping over 8% on Thursday. QuickLogic Corporation (NASDAQ: QUIK) rose 14.7% to $6.15 in pre-market trading. QuickLogic reported a strategic investment by current shareholders. The company said it expects Q3 revenue of $3.8 million to $3.9 million. Paltalk, Inc. (NASDAQ: PALT) rose 12.3% to $1

  • Benzinga

    Minerva Posts Positive Bioequivalence Results For Schizophrenia Candidate Formulations

    Minerva Neurosciences Inc (NASDAQ: NERV) announced results from a bioequivalence study comparing roluperidone formulations used in Phase 2b and Phase 3 trials and the planned commercial formulation. Related Link: Minerva's Schizophrenia Candidate Shows Long Term Improvement In Negative Symptoms, Functioning The 48-subject study met all key pharmacokinetic (PK) objectives, and the data demonstrate bioequivalence across the various formulations. The data showed comparability under the fasted condi